What is the role of bisphosphonate therapy in the treatment of hormone-refractory prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print


Bisphosphonates, which are stable analogues of calcium pyrophosphate, inhibit osteoclastic activity in bone, relieving bone pain. These agents may also limit progression of prostate cancer and are also being studied for the treatment of osteoporosis induced by androgen-deprivation therapy (ADT). [39] More recently, zoledronic acid (Zometa) has shown further promising results.

Bisphosphonates used in conjunction with antiangiogenic factors may increase the risk of osteonecrosis of the jaw over bisphosphonates alone. This may warrant pretreatment evaluation of dentition.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!